Year in Review: Updates in Treating Myelofibrosis - Episode 3

Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

,

Andrew Kuykendall, MD, reviews data from TRANSFORM-1 on navitoclax plus ruxolitinib for untreated myelofibrosis, highlighting consistent response rates, no significant symptom improvement with the combination, and challenges managing thrombocytopenia caused by navitoclax, despite its activity and potential as a second-line treatment option.

EP. 1: How JAK Inhibitors Have Shaped the Landscape of MF
EP. 2: Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2
Now Viewing
EP. 3: Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1
EP. 4: Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib
EP. 5: Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
EP. 6: Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
EP. 7: Future Directions in Combination Therapies for Myelofibrosis
EP. 8: Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF
EP. 9: The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib
EP. 10: Selection and Sequencing of JAK Inhibitors for Patients With MF
EP. 11: Individualizing Therapy Goals for Patients With Myelofibrosis
EP. 12: Emerging Treatments for Myelofibrosis

Related Content:

Year in Review: Updates in Treating MyelofibrosisMyeloproliferative NeoplasmsHematologic Oncology
An Era of Firsts in CML: Asciminib Challenges SOC TKIs
Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management